Rationale & Objective: Disorders of bone and mineral metabolism frequently develop with advanced kidney disease, may be exacerbated by immunosuppression after kidney transplantation, and increase the risk of fractures.

Study Design: Retrospective database study.

Setting & Participants: Kidney-only transplant recipients aged ≥18 years from 2005 to 2016 in the United States captured in US Renal Data System records, which integrate Organ Procurement and Transplantation Network/United Network for Organ Sharing records with Medicare billing claims.

Exposures: Various immunosuppression regimens in the first 3 months after kidney transplantation.

Outcomes: The development of fractures, as ascertained using diagnostic codes on Medicare billing claims.

Analytical Approach: We used multivariable Cox regression with inverse probability propensity weighting to compare the incidence of fractures >3 months-to-3 years after kidney transplantation associated with various immunosuppression regimens compared to a reference regimen of antithymocyte globulin (TMG) or alemtuzumab (ALEM) with tacrolimus + mycophenolic acid + prednisone using inverse probability treatment weighting.

Results: Overall, fractures were identified in 7.5% of kidney transplant recipients (women, 8.8%; men, 6.7%; age < 55 years, 5.9%; age ≥ 55 years, 9.3%). In time-varying regression, experiencing a fracture was associated with a substantially increased risk of subsequent death within 3 months (adjusted hazard ratio [aHR], 3.06; 95% confidence interval [CI], 2.45-3.81). Fractures were also associated with increased Medicare spending (first year: $5,122; second year: $10,890; third year: $11,083; [P < 0.001]). Induction with TMG or ALEM and the avoidance or early withdrawal of steroids significantly reduced the risk of fractures in younger (aHR, 0.63; 95% CI, 0.54-0.79) and older (aHR, 0.83; 95% CI, 0.74-0.94) patients. The avoidance or early withdrawal of steroids with any induction was associated with a reduced risk of fractures in women.

Limitations: This was a retrospective study which lacked data on immunosuppression levels.

Conclusions: Fractures after kidney transplantation are associated with significantly increased mortality risk and costs. The early avoidance or early withdrawal of steroids after induction with TMG or ALEM reduces the risk of fractures after kidney transplantation and should be considered for patients at high-risk of this complication, including older adults and women.

C hronic kidney disease-mineral and bone disorders (CKD-MBD) affect many patients who progress to chronic kidney failure and contribute to increased morbidity and even mortality.1-3 CKD-MBD results in clinically evident osteoporosis in up to 66% of patients with kidney failure,1,4 contributing to long-bone fractures, vertebral compression fractures, and other complications.3,6,7 CKD-MBD is the outcome of chronic alternations in calcium or phosphorus metabolism, leading to hyperparathyroidism, alterations in the activity of fibroblastic growth factor-23, and impaired osteoblastic activity.3,7-5

Kidney transplantation has been conclusively demonstrated to offer the best treatment for chronic kidney failure, extending survival, improving the quality of life, and reducing life-time medical expenditures.3-16 Unfortunately, there is historical evidence that immunosuppressive medications vital for kidney allograft survival contribute to further deterioration of bone health after kidney transplantation.3,11-15 Although there are many factors that affect bone health, the long-term use of glucocorticoids after transplantation remains the key factor that exacerbates osteoporosis in patients with CKD-MBD who have undergone transplantation.1-3,16 Immediately following kidney transplantation, there is rapid loss of bone mass because of decreased bone formation as a result of glucocorticoid therapy.17 Bone mineral density has been shown to decrease by 4%-10% in the first 6 months after transplantation.18 This reduction in bone density aligns with prior findings that up to 22.5% of kidney transplant recipients experienced a fracture within 5 years,2,711,15,19-24 which is higher than the rates in the general population and in patients who require maintenance dialysis.3-7,7 Post-transplantation fractures resulted in increased health care costs and up to a 60% increase in posttransplantation mortality.2

As patient survival following kidney transplantation has continued to improve, minimizing the impact of immunosuppression-associated comorbidities on patient health is an important research focus.
The primary outcome of interest was a clinically diagnosed fracture >3 months-to-3 years after kidney transplantation. We identified fractures using Medicare billings claims based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM, through September 2015), and the Tenth Revision (ICD-10-CM, through September 2015). The diagnosis of a fracture predicted a 3-fold increased risk of death and higher Medicare spending. We observed benefits of corticosteroid-sparing regimens with appropriate induction therapy on the post-transplantation risk of fractures in older and younger adults. These findings support consideration of the risk of nonimmune complications along with rejection risk when selecting immunosuppression regimens for kidney transplant recipients.

**Definition of Immunosuppression Regimens**

We determined the use of induction agents based on center-reported data from the OPTN. We determined early immunosuppression regimens based on Medicare pharmacy claims for immunosuppression agents submitted within the first 3 months after transplantation and reimbursed through Part B or D benefits. Based on induction and maintenance immunosuppression regimens, we categorized the patients into 7 mutually exclusive study regimens, which are as follows (Fig S1):

1. **Triple maintenance (tacrolimus [Tac] + mycophenolic acid/azathioprine + prednisone [Pred]), after T-cell–depleting induction: antithymocyte globulin (TMG) or alemtuzumab (ALEM) (reference regimen).**
2. **Triple maintenance after interleukin 2 receptor antibody (IL2rAb) induction: IL2rAb + triple therapy.**
3. **Steroid avoidance/withdrawal after T-cell–depleting induction: TMG or ALEM + no prednisone.**
4. **Steroid avoidance after IL2rAb induction: IL2rAb + no Pred.**
5. **Antimetabolite avoidance: tacrolimus [Tac] alone or Tac + Pred with any induction.**
6. **Mammalian target of rapamycin inhibitor (mTORi)-based regimens.**
7. **Cyclosporine A (CsA)-based regimens.**

**Outcome Measures**

The primary outcome of interest was a clinically diagnosed fracture >3 months-to-3 years after kidney transplantation. We identified fractures using Medicare billings claims based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM, through September 2015), and the Tenth Revision (ICD-10-CM, through September 2015). The study identified kidney-only transplant recipients aged ≥18 years from 2005 to 2016 in the United States. The recipients were categorized as younger (<55 years) and older (≥55 years) adults. Recipient sex was determined based on the sex reported in the listing for kidney transplantation. Patients were selected for inclusion if they had Medicare as the primary payer at the time of transplantation and had Medicare-reimbursed prescriptions and fills for immunosuppression in the first 3 months after transplantation. This study was deemed as exempt from human subjects review by the Saint Louis University Institutional Review Board. Patients with primary insurance other than Medicare were excluded from this analysis.

**Data Source and Sampling**

Study data were drawn from US Renal Data System records, which integrate Organ Procurement and Transplantation Network (OPTN)/United Network for Organ Sharing (UNOS) records with Medicare billing claims. The study identified kidney-only transplant recipients aged ≥18 years from 2005 to 2016 in the United States. The recipients were categorized as younger (<55 years) and older (≥55 years) adults. Recipient sex was determined based on the sex reported in the listing for kidney transplantation. Patients were selected for inclusion if they had Medicare as the primary payer at the time of transplantation and had Medicare-reimbursed prescriptions and fills for immunosuppression in the first 3 months after transplantation. This study was deemed as exempt from human subjects review by the Saint Louis University Institutional Review Board. Patients with primary insurance other than Medicare were excluded from this analysis.

**Methods**

**Data Source and Sampling**

Study data were drawn from US Renal Data System records, which integrate Organ Procurement and Transplantation Network (OPTN)/United Network for Organ Sharing (UNOS) records with Medicare billing claims. The study identified kidney-only transplant recipients aged ≥18 years from 2005 to 2016 in the United States. The recipients were categorized as younger (<55 years) and older (≥55 years) adults. Recipient sex was determined based on the sex reported in the listing for kidney transplantation. Patients were selected for inclusion if they had Medicare as the primary payer at the time of transplantation and had Medicare-reimbursed prescriptions and fills for immunosuppression in the first 3 months after transplantation. This study was deemed as exempt from human subjects review by the Saint Louis University Institutional Review Board. Patients with primary insurance other than Medicare were excluded from this analysis.

**Definition of Immunosuppression Regimens**

We determined the use of induction agents based on center-reported data from the OPTN. We determined early immunosuppression regimens based on Medicare pharmacy claims for immunosuppression agents submitted within the first 3 months after transplantation and reimbursed through Part B or D benefits. Based on induction and maintenance immunosuppression regimens, we categorized the patients into 7 mutually exclusive study regimens, which are as follows (Fig S1):

1. **Triple maintenance (tacrolimus [Tac] + mycophenolic acid/azathioprine + prednisone [Pred]), after T-cell–depleting induction: antithymocyte globulin (TMG) or alemtuzumab (ALEM) (reference regimen).**
2. **Triple maintenance after interleukin 2 receptor antibody (IL2rAb) induction: IL2rAb + triple therapy.**
3. **Steroid avoidance/withdrawal after T-cell–depleting induction: TMG or ALEM + no prednisone.**
4. **Steroid avoidance after IL2rAb induction: IL2rAb + no Pred.**
5. **Antimetabolite avoidance: tacrolimus [Tac] alone or Tac + Pred with any induction.**
6. **Mammalian target of rapamycin inhibitor (mTORi)-based regimens.**
7. **Cyclosporine A (CsA)-based regimens.**

**Outcome Measures**

The primary outcome of interest was a clinically diagnosed fracture >3 months-to-3 years after kidney transplantation. We identified fractures using Medicare billings claims based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM, through September 2015), and the Tenth Revision (ICD-10-CM, through September 2015). The diagnosis of a fracture predicted a 3-fold increased risk of death and higher Medicare spending. We observed benefits of corticosteroid-sparing regimens with appropriate induction therapy on the post-transplantation risk of fractures in older and younger adults. These findings support consideration of the risk of nonimmune complications along with rejection risk when selecting immunosuppression regimens for kidney transplant recipients.

**Definition of Immunosuppression Regimens**

We determined the use of induction agents based on center-reported data from the OPTN. We determined early immunosuppression regimens based on Medicare pharmacy claims for immunosuppression agents submitted within the first 3 months after transplantation and reimbursed through Part B or D benefits. Based on induction and maintenance immunosuppression regimens, we categorized the patients into 7 mutually exclusive study regimens, which are as follows (Fig S1):

1. **Triple maintenance (tacrolimus [Tac] + mycophenolic acid/azathioprine + prednisone [Pred]), after T-cell–depleting induction: antithymocyte globulin (TMG) or alemtuzumab (ALEM) (reference regimen).**
2. **Triple maintenance after interleukin 2 receptor antibody (IL2rAb) induction: IL2rAb + triple therapy.**
3. **Steroid avoidance/withdrawal after T-cell–depleting induction: TMG or ALEM + no prednisone.**
4. **Steroid avoidance after IL2rAb induction: IL2rAb + no Pred.**
5. **Antimetabolite avoidance: tacrolimus [Tac] alone or Tac + Pred with any induction.**
6. **Mammalian target of rapamycin inhibitor (mTORi)-based regimens.**
7. **Cyclosporine A (CsA)-based regimens.**

**Outcome Measures**

The primary outcome of interest was a clinically diagnosed fracture >3 months-to-3 years after kidney transplantation. We identified fractures using Medicare billings claims based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM, through September 2015), and the Tenth Revision (ICD-10-CM, through September 2015). The diagnosis of a fracture predicted a 3-fold increased risk of death and higher Medicare spending. We observed benefits of corticosteroid-sparing regimens with appropriate induction therapy on the post-transplantation risk of fractures in older and younger adults. These findings support consideration of the risk of nonimmune complications along with rejection risk when selecting immunosuppression regimens for kidney transplant recipients.
starting October 2015) diagnosis codes (250.x and E08-E13, respectively) that occurred or persisted >3 months-to-3 years after transplantation (Table S1). Mortality was identified using the transplant registry data. The cost of care was quantified based on aggregated Part A and B claims from discharge to the third year after transplantation.

**Statistical Analysis**

The clinical characteristics of the study sample were described as proportions. We grouped continuous variables into clinically relevant categories. Rather than imputing missing data, for the small number of absent values, we classified the missing data as "not reported" and included a missing category in the regression analyses. We compared the distributions of clinical characteristics according to immunosuppression regimen using the \( \chi^2 \) test.

The cumulative incidence of fractures >3 months-to-3 years after kidney transplantation with each immunosuppression regimen was estimated using the Kaplan-Meier method, with the origin time for models at 3 months after transplantation (i.e., after the period of immunosuppression classification), which was chosen with the expectation that immunosuppression generally stabilizes by this point. The incidence of fractures with each immunosuppression regimen was compared to incidence with the reference regimen of TMG or ALEM + triple therapy using the log-rank test. We modeled the associations (adjusted hazard ratios [aHRs] and 95% confidence intervals [CIs]) between the selection of immunosuppression regimen and the development of fractures using the Cox proportional hazard analysis with inverse probability treatment weighting (IPTW). IPTW uses propensity weights to create "analytic" samples that are more similar and allow better estimation of the independent impact of immunosuppression regimen selection on the development of fractures. To construct the weights, we modeled the probability of development of a fracture, comparing each immunosuppression regimen with the reference regimen (TMG or ALEM + triple therapy) based on the patients’ age, sex, race, number of human leukocyte antigen mismatches, panel-reactive antibody, and hepatitis C virus status; the age of donor; the type of donor (living or deceased, by Kidney Donor Profile Index [KDPI] level). The weights were stabilized; a robust sandwich estimator was used to prevent the underestimation of variance. Good balance was achieved for all confounders (standardized absolute mean difference <0.2 for all covariates and overall difference <0.1 for all models).

The patients were followed for up to 3 years after transplantation, death, or loss of Medicare coverage. We performed prespecified subgroup analyses based on age (<55 vs ≥55 years) and sex and investigated the potential interaction of immunosuppression regimen with age and sex on the incidence of fractures. We also explored the impact of fracture as a time-dependent exposure on the risk of subsequent mortality using multivariable, time-varying Cox regression, including adjustments for donor and recipient factors, per previous methods. Based on exposure time, the risk of mortality associated with fractures after kidney transplantation was classified into within 3 months and >3 months after the diagnosis of a fracture. Analyses stratified by age and sex were included, as per previous methods.

The marginal cost impact of fractures on costs in years 1, 2, and 3 after transplantation were computed using ordinary least squares regression as follows: \( E(Y) = \beta_0 \cdot X_1 + \beta_1 \cdot X_2 + \ldots + \beta_k \cdot X_k \), where \( E(Y) \) is the Medicare payments within a period of interest, \( X_k \) is the value of a given predictor variable, and \( \beta_k \) is the marginal costs associated with a 1-unit change in a given variable after adjustment for other observed factors in the model. Thus, for binary variables such as fractures, the \( \beta_k \) parameters quantify the marginal costs associated with the diagnosis, adjusted for the recipient, donor, and transplant factors. Cost period models were also adjusted for other baseline factors, as previously described. The costs of death were included because death may be a consequence of a fracture.

A P value of <0.05 was considered statistically significant. The management and analysis of data were performed using SAS, version 9.4 (SAS Institute Inc.).

**RESULTS**

**Sample Characteristics and the Use of Immunosuppression Regimens**

Among 193,984 kidney transplant recipients in the study period, 67,362 had Medicare insurance at the time of transplantation. The patients in the study sample were largely similar to those in the overall population who have undergone kidney transplantation: 31,740 (47.1%) were aged ≥55 years, 40,723 (60.5%) were men, 30,875 (45.8%) were White, 20,200 (30.0%) were African American, 22,668 (33.7%) had a body mass index (BMI) of ≥30 kg/m², and 51,462 (76.4%) received dialysis for >24 months before kidney transplantation (Table S2). The reference regimen (TMG or ALEM + triple therapy) was the most commonly used regimen (30,134; 44.7%), followed by the TMG or ALEM + no Pred (13,055; 19.4%), IL2rAb + triple therapy (10,836; 16.1%), mTORi-based (5,043; 7.5%), and CsA-based (4,707; 7.0%) regimens. IL2rAb + no Pred (1,553; 2.3%) and Tac alone or Tac + Pred with any induction (2,034; 3.0%) were rarely used (Table 1).

**Clinical Correlates of Posttransplantation Fractures**

The incidence of fractures >3 months-to-3 years after kidney transplantation was 7.5%, which varied by sex (women, 8.8%; men, 6.7%), age (<55 years, 5.9%; ≥55 years, 9.3%), and other characteristics (Table 2). After adjustment for other donor and recipient characteristics, the adjusted risk of fractures remained elevated for older patients (≥55 years: aHR, 1.26; 95% CI, 1.18-1.35) and women (aHR, 1.42; 95% CI, 1.33-1.52). Conversely, Black race (aHR, 0.54; 95% CI, 0.49-0.59), Hispanic
| Characteristic                     | TMG or ALEM + Triple Therapy (Reference) n (%) | IL2rAb + Triple Therapy n (%) | TMG or ALEM + No Pred n (%) | IL2rAb + No Pred n (%) | Tac, Tac + Pred n (%) | mTORi-based n (%) | CsA-based n (%) |
|-----------------------------------|-----------------------------------------------|-------------------------------|------------------------------|------------------------|----------------------|-------------------|-----------------|
| Age, y                            |                                               |                               |                              |                        |                      |                   |                 |
| 18-54                             | 17,355 (57.6)                                | 5,084 (46.9)                  | 6,540 (50.1)                 | 537 (34.6)             | 1,027 (50.5)         | 2,827 (56.1)     | 2,252 (47.8)    |
| ≥55                               | 12,779 (42.4)                                | 5,752 (53.1)                  | 6,151 (49.9)                 | 1,016 (65.4)           | 1,007 (49.5)         | 2,216 (43.9)     | 2,455 (52.2)    |
| Sex                               |                                               |                               |                              |                        |                      |                   |                 |
| Male                              | 17,242 (57.2)                                | 6,987 (64.5)                  | 8,196 (62.8)                 | 994 (64.0)             | 1,247 (61.3)         | 3,200 (63.5)     | 2,857 (60.7)    |
| Female                            | 12,892 (42.8)                                | 3,849 (35.5)                  | 4,859 (37.2)                 | 559 (36.0)             | 787 (38.7)           | 1,843 (36.6)     | 1,850 (39.3)    |
| Race                              |                                               |                               |                              |                        |                      |                   |                 |
| White                             | 12,208 (40.5)                                | 5,525 (51.0)                  | 6,212 (47.6)                 | 911 (58.7)             | 1,061 (52.2)         | 2,535 (50.3)     | 2,423 (51.5)    |
| African American                  | 10,777 (35.8)                                | 2,517 (23.2)                  | 3,596 (27.6)                 | 260 (16.7)             | 548 (26.9)           | 1,467 (29.1)     | 1,035 (22.0)    |
| Hispanic                          | 5,454 (18.1)                                 | 1,961 (18.1)                  | 2,590 (19.2)                 | 270 (17.4)             | 292 (14.4)           | 775 (15.4)       | 817 (17.4)      |
| Other                             | 1,695 (5.6)                                  | 833 (7.7)                     | 738 (5.7)                    | 112 (7.2)              | 133 (6.5)            | 266 (5.3)        | 432 (9.2)       |
| Employment status                 |                                               |                               |                              |                        |                      |                   |                 |
| Working                           | 5,178 (17.2)                                 | 1,895 (17.5)                  | 2,568 (19.7)                 | 290 (18.7)             | 440 (21.6)           | 855 (17.0)       | 697 (14.8)      |
| Not working                       | 22,413 (74.4)                                | 8,131 (75.0)                  | 9,342 (71.6)                 | 1,176 (75.7)           | 1,406 (69.1)         | 3,815 (75.7)     | 3,409 (72.4)    |
| Not reported                      | 2,543 (8.4)                                  | 810 (7.5)                     | 1,145 (8.8)                  | 87 (5.6)               | 188 (9.2)            | 373 (7.4)        | 601 (12.8)      |
| Body mass index, kg/m²            |                                               |                               |                              |                        |                      |                   |                 |
| <18.5                             | 734 (2.4)                                    | 269 (2.5)                     | 211 (1.6)                    | 43 (2.8)               | 58 (2.9)             | 120 (2.4)        | 109 (2.3)       |
| 18.5-24.9                         | 9,018 (29.9)                                 | 3,360 (31.0)                  | 3,549 (27.2)                 | 472 (30.4)             | 618 (30.4)           | 1,498 (29.7)     | 1,398 (29.7)    |
| 25.0-29.9                         | 9,683 (32.1)                                 | 3,727 (34.4)                  | 4,178 (32.0)                 | 562 (36.2)             | 656 (32.3)           | 1,740 (34.5)     | 1,505 (32)      |
| ≥30.0                             | 10,328 (34.3)                                | 3,386 (31.3)                  | 4,687 (35.9)                 | 463 (29.8)             | 624 (30.7)           | 1,590 (31.5)     | 1,590 (33.8)    |
| Not reported                      | 371 (1.2)                                    | 94 (0.9)                      | 430 (3.3)                    | 13 (0.8)               | 78 (3.8)             | 95 (1.9)         | 105 (2.2)       |
| Comorbid conditions               |                                               |                               |                              |                        |                      |                   |                 |
| Hypertension                      | 9,531 (31.6)                                 | 3,495 (32.3)                  | 4,267 (32.7)                 | 530 (34.1)             | 652 (32.1)           | 1,834 (36.4)     | 1,593 (33.8)    |
| Diabetes mellitus                 | 10,246 (34.0)                                | 4,106 (37.9)                  | 5,155 (39.5)                 | 665 (42.8)             | 761 (37.4)           | 1,790 (35.5)     | 1,892 (40.2)    |
| Coronary artery disease           | 997 (3.3)                                    | 459 (4.2)                     | 541 (4.1)                    | 103 (6.6)              | 94 (4.6)             | 293 (5.8)        | 270 (5.7)       |
| Cerebral vascular disease         | 159 (0.5)                                    | 75 (0.7)                      | 113 (0.9)                    | 12 (0.8)               | 7 (0.3)              | 51 (1.0)         | 50 (1.1)        |
| Peripheral vascular disease       | 2,146 (7.1)                                  | 901 (8.3)                     | 1,033 (7.9)                  | 154 (9.9)              | 119 (5.9)            | 355 (7.0)        | 397 (8.4)       |
| COPD                              | 113 (0.4)                                    | 47 (0.4)                      | 72 (0.6)                     | 16 (1.0)               | 11 (0.5)             | 38 (0.8)         | 39 (0.8)        |
| Hepatitis C positive              | 1,558 (5.2)                                  | 644 (5.9)                     | 520 (4.0)                    | 104 (6.7)              | 115 (5.7)            | 238 (4.7)        | 369 (7.8)       |
| Kidney functional status, activities with: |                                               |                               |                              |                        |                      |                   |                 |
| No assistance                     | 26,057 (86.5)                                | 8,948 (82.6)                  | 11,741 (89.9)                | 1,321 (85.1)           | 1,706 (83.9)         | 3,900 (77.3)     | 3,935 (83.6)    |
| Some assistance                   | 2,860 (9.5)                                  | 1,118 (10.3)                  | 781 (6.0)                    | 130 (8.4)              | 129 (6.3)            | 842 (16.7)       | 418 (8.9)       |
| Total assistance                  | 523 (1.7)                                    | 233 (2.2)                     | 303 (2.3)                    | 24 (1.6)               | 22 (1.1)             | 72 (1.4)         | 74 (1.6)        |
| Not reported                      | 694 (2.3)                                    | 537 (5.0)                     | 230 (1.8)                    | 78 (5.0)               | 177 (8.7)            | 229 (4.5)        | 280 (6.0)       |

(Continued)
Table 1 (Cont’d). Distributions of Baseline Kidney Transplant Recipient Traits, Donor Type, and Transplant Factors According to Early Immunosuppression Regimen Use (N = 67,362)

| Characteristic                  | TMG or ALEM + Triple Therapy (Reference) n (%) | IL2rAb + Triple Therapy n (%) | TMG or ALEM + No Pred n (%) | IL2rAb + No Pred n (%) | Tac, Tac + Pred n (%) | mTORi-based n (%) | CsA-based n (%) |
|---------------------------------|-----------------------------------------------|-------------------------------|-----------------------------|------------------------|----------------------|-------------------|------------------|
| Cause of ESKD                  |                                               |                               |                             |                        |                      |                   |                  |
| Hypertension                    | 6,985 (23.2)                                  | 2,276 (21.0)                  | 2,886 (22.1)                | 294 (18.9)             | 399 (19.6)           | 1,203 (23.9)      | 942 (20.0)       |
| Diabetes mellitus               | 8,360 (27.7)                                  | 3,409 (31.5)                  | 4,382 (33.6)                | 562 (36.2)             | 598 (29.4)           | 1,438 (28.5)      | 1,535 (32.6)     |
| Glomerulonephritis              | 9,815 (32.6)                                  | 3,137 (29.0)                  | 3,609 (27.6)                | 411 (26.5)             | 619 (30.4)           | 1,492 (29.6)      | 1,380 (29.3)     |
| Polycystic kidney disease       | 2,202 (7.3)                                   | 841 (7.8)                     | 1,128 (8.6)                 | 111 (7.2)              | 179 (8.8)            | 437 (8.7)         | 352 (7.5)        |
| Other                           | 2,772 (9.2)                                   | 1,173 (10.8)                  | 1,050 (8.0)                 | 175 (11.3)             | 239 (11.8)           | 473 (9.4)         | 488 (10.6)       |
| Duration of dialysis, mo        |                                               |                               |                             |                        |                      |                   |                  |
| None (pre-emptive)              | 1,163 (3.9)                                   | 913 (8.4)                     | 899 (6.9)                   | 182 (11.7)             | 173 (8.5)            | 309 (6.1)         | 379 (8.1)        |
| >0-24                           | 4,157 (13.8)                                  | 2,466 (22.8)                  | 2,437 (18.7)                | 438 (28.2)             | 428 (21.0)           | 987 (19.6)        | 933 (19.8)       |
| 25-60                           | 10,544 (35.0)                                 | 3,934 (36.3)                  | 5,225 (40.0)                | 537 (34.6)             | 766 (37.7)           | 1,939 (38.5)      | 1,637 (34.8)     |
| >60                             | 14,264 (47.3)                                 | 3,518 (32.5)                  | 4,487 (34.4)                | 394 (25.4)             | 663 (32.6)           | 1,806 (35.8)      | 1,748 (37.1)     |
| Not reported                    | 6 (0.0)                                       | 5 (0.1)                       | 7 (0.1)                     | 2 (0.1)                | 4 (0.2)              | 2 (0.0)           | 10 (0.2)         |
| Most current PRA level, %       |                                               |                               |                             |                        |                      |                   |                  |
| <10                             | 18,092 (60.0)                                 | 8,632 (79.7)                  | 10,023 (76.8)               | 1,247 (80.3)           | 1,473 (72.4)         | 3,542 (70.2)      | 3,428 (72.8)     |
| 10-79                           | 6,332 (21)                                    | 1,370 (12.6)                  | 1,799 (13.8)                | 164 (10.6)             | 322 (15.8)           | 795 (15.8)        | 700 (14.9)       |
| ≥80                             | 4,994 (16.6)                                  | 423 (3.9)                     | 785 (6.0)                   | 34 (2.2)               | 153 (7.5)            | 371 (7.4)         | 350 (7.4)        |
| Not reported                    | 716 (2.4)                                     | 411 (3.8)                     | 448 (3.4)                   | 108 (7.0)              | 86 (4.2)             | 335 (6.6)         | 229 (4.9)        |
| HLA mismatches                  |                                               |                               |                             |                        |                      |                   |                  |
| 0 A, B, DR                      | 1,831 (6.1)                                   | 818 (7.6)                     | 791 (6.1)                   | 237 (15.3)             | 153 (7.5)            | 350 (6.9)         | 409 (8.7)        |
| 0 DR                            | 3,285 (10.9)                                  | 1,093 (10.1)                  | 1,494 (11.4)                | 158 (10.2)             | 227 (11.2)           | 511 (10.1)        | 512 (10.9)       |
| Other                           | 25,018 (83.0)                                 | 8,925 (82.4)                  | 10,770 (82.5)               | 1,158 (74.6)           | 1,654 (81.3)         | 4,182 (82.9)      | 3,786 (80.4)     |
| Cold ischemia time, h           |                                               |                               |                             |                        |                      |                   |                  |
| ≤12                            | 11,398 (37.8)                                 | 5,137 (47.4)                  | 4,999 (38.3)                | 736 (47.4)             | 811 (39.9)           | 2,126 (42.2)      | 1,862 (39.6)     |
| 13-24                          | 12,749 (42.3)                                 | 3,917 (36.2)                  | 4,769 (36.5)                | 486 (31.3)             | 757 (37.2)           | 1,902 (37.7)      | 1,764 (37.5)     |
| 25-36                          | 3,919 (13.0)                                  | 1,056 (9.8)                   | 1,670 (12.8)                | 118 (7.6)              | 237 (11.7)           | 568 (11.3)        | 543 (11.5)       |
| ≥37                            | 897 (3.0)                                     | 163 (1.5)                     | 678 (5.2)                   | 25 (1.6)               | 60 (3.0)             | 147 (2.9)         | 102 (2.2)        |
| Not reported                    | 1,171 (3.9)                                   | 563 (5.2)                     | 939 (7.2)                   | 188 (12.1)             | 169 (8.3)            | 300 (6.0)         | 436 (9.3)        |
| Previous organ transplant       |                                               |                               |                             |                        |                      |                   |                  |
| Yes                             | 5,993 (19.9)                                  | 1,009 (9.3)                   | 1,160 (8.9)                 | 133 (8.6)              | 336 (16.5)           | 786 (15.6)        | 714 (15.2)       |
| No                              | 24,141 (80.1)                                 | 9,827 (90.7)                  | 11,895 (91.1)               | 1,420 (91.4)           | 1,698 (83.5)         | 4,257 (84.4)      | 3,993 (84.8)     |
| Donor type                      |                                               |                               |                             |                        |                      |                   |                  |
| Living donor                    | 5,301 (17.6)                                  | 3,137 (29.0)                  | 3,425 (26.2)                | 600 (38.6)             | 490 (24.1)           | 1,184 (23.5)      | 1,193 (25.4)     |
| Deceased, KDPI < 20             | 4,962 (16.5)                                  | 1,824 (16.8)                  | 1,924 (14.7)                | 231 (14.9)             | 420 (20.7)           | 732 (14.5)        | 775 (16.5)       |
| Deceased, KDPI 20-85            | 17,400 (57.7)                                 | 5,062 (46.7)                  | 6,562 (50.3)                | 594 (38.3)             | 962 (47.3)           | 2,585 (51.3)      | 2,381 (50.6)     |
Ethnicity (aHR, 0.67; 95% CI, 0.61-0.74), other race (aHR, 0.55; 95% CI, 0.48-0.64), and elevated BMI >30 kg/m² (aHR, 0.90; 95% CI, 0.83-0.988) were protective against fracture risk.

**Associations of Fracture With Mortality**

Overall, mortality after kidney transplantation was significantly increased in patients who experienced a fracture >3 months-to-3 years after the kidney transplantation (Fig 1). The risk of death in patients diagnosed with a fracture within the first 3 months of diagnosis was >3-fold higher than that in patients without a fracture (aHR for death, 3.06; 95% CI, 2.45-3.81; Table 3). After 3 months, the risk of death remained elevated in patients with fractures (aHR, 1.68; 95% CI, 1.48-1.91). Other characteristics associated with the risk of death included older age (aHR, 1.03; 95% CI, 1.03-1.04; per year), female sex (aHR, 0.90; 95% CI, 0.87-0.93), Black race (aHR, 0.87; 95% CI, 0.83-0.90), Hispanic ethnicity (aHR, 0.68; 95% CI, 0.66-0.73), and other race (aHR, 0.71; 95% CI, 0.66-0.76). When the risk of death within 3 months was examined within subgroups, fractures were associated with a greater relative risk of death in men (vs. women) and older adults (vs. younger adults) (Figure 1; Table 3).

**Impact of Fractures on Medicare Payments**

After transplantation, the mean spending varied significantly according to the presence or absence of fracture diagnosis. Fractures within the first year resulted in a risk-adjusted incremental cost of care of $5,122 (Fig S2). In the second year after transplantation, a new fracture was associated with increased spending of $10,890, whereas patients with fractures in the prior year incurred $1,929 higher year 2 expenditures. In the third year after transplantation, new fractures were associated with incremental spending of $11,083, and prior fractures were associated with $1,844 higher year 3 Medicare payments. Other factors associated with increased spending included age, sex, cold ischemic time, kidney donor profile index, and diagnosis (Table S3).

**Incidence of Fractures According to Immunosuppression Regimen, Age, and Sex**

The choice of immunosuppression regimen significantly affects the incidence of fractures across all ages (Fig 2A) and both sexes (Fig 2B). Furthermore, the impact of immunosuppression varied among subgroups. Younger patients (<55 years) treated with TMG or ALEM + no Pred experienced significantly fewer fractures than those who received the reference immunosuppression regimen (TMG or ALEM + triple therapy; 4.0% vs 6.3%, respectively; P < 0.0001). No other regimen was associated with significantly lower rates, although the mTORi-based, CsA-based, and Tac + Pred regimens were all associated with a numerically greater incidence. In the multivariable, risk-adjusted analysis, both TMG or ALEM + no Pred (aHR, 0.63; 95% CI, 0.54-0.73) and IL2rAb + triple therapy (aHR, 0.81; 95% CI, 0.70-0.94) reduced the risk of fractures (Fig 2A).
### Table 2. Cumulative Incidence of Fractures >3 Months-to-3 Years After Kidney Transplantation by Baseline Clinical Characteristics and Adjusted Correlates of Fracture Risk

| Baseline Characteristic                  | Cumulative Incidence of Fractures >3 m-to-3 y After Kidney Transplantation | Adjusted Correlates of Fracture Risk > 3 m-to-3 y After Kidney Transplantation |
|-----------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
|                                         | % (95% CI)                                                                    | aHR (95% CI)                                                                   |
| **Age, y**                              |                                                                              |                                                                              |
| 18-54                                   | 5.9 (5.6-6.2)                                                                | Reference                                                                     |
| ≥55                                     | 9.3 (8.9-9.7)                                                                | 1.26 (1.18-1.35)                                                              |
| **Sex**                                 |                                                                              |                                                                              |
| Male                                    | 6.7 (6.4-7.0)                                                                | Reference                                                                     |
| Female                                  | 8.8 (8.4-9.2)                                                                | 1.42 (1.33-1.52)                                                              |
| **Race**                                |                                                                              |                                                                              |
| White                                   | 9.4 (9.0-9.8)                                                                | Reference                                                                     |
| African American                        | 5.4 (5.0-5.7)                                                                | 0.54 (0.49-0.59)                                                              |
| Hispanic                                | 6.7 (6.2-7.2)                                                                | 0.67 (0.61-0.74)                                                              |
| Other                                   | 5.6 (4.9-6.5)                                                                | 0.55 (0.48-0.64)                                                              |
| **Employment status**                   |                                                                              |                                                                              |
| Working                                 | 5.6 (5.1-6.1)                                                                | 0.78 (0.71-0.86)                                                              |
| Not working                             | 8.1 (7.8-8.4)                                                                | Reference                                                                     |
| Not reported                            | 6.3 (5.6-7.0)                                                                | 0.84 (0.75-0.95)                                                              |
| **Body mass index, kg/m²**              |                                                                              |                                                                              |
| <18.5                                   | 7.9 (6.5-9.6)                                                                | 1.10 (0.89-1.36)                                                              |
| 18.5-24.9                               | 7.4 (7.0-7.8)                                                                | Reference                                                                     |
| 25.0-29.9                               | 7.5 (7.1-7.9)                                                                | 0.94 (0.87-1.02)                                                              |
| ≥30.0                                   | 7.7 (7.3-8.1)                                                                | 0.90 (0.83-0.98)                                                              |
| Not reported                            | 6.4 (5.0-8.0)                                                                | 0.71 (0.55-0.92)                                                              |
| **Comorbid conditions**                 |                                                                              |                                                                              |
| Hypertension                            | 6.4 (6.0-6.7)                                                                | 0.87 (0.77-0.98)                                                              |
| Diabetes mellitus                       | 10.4 (9.9-10.8)                                                              | 1.22 (1.07-1.39)                                                              |
| Coronary artery disease                 | 8.9 (7.9-10.2)                                                               | 1.06 (0.90-1.24)                                                              |
| Cerebrovascular disease                 | 9.4 (6.9-12.7)                                                               | 1.08 (0.77-1.51)                                                              |
| Peripheral vascular disease             | 11.3 (10.3-12.3)                                                             | 1.25 (1.13-1.39)                                                              |
| COPD                                    | 10.3 (7.3-14.4)                                                              | 1.15 (0.79-1.66)                                                              |
| Hepatitis C positive                    | 9.2 (8.2-10.4)                                                               | 1.30 (1.14-1.49)                                                              |
| **Kidney functional status, activities with:** |                                                                              |                                                                              |
| No assistance                           | 7.1 (6.9-7.4)                                                                | Reference                                                                     |
| Some assistance                         | 9.7 (8.8-10.6)                                                               | 1.20 (1.09-1.33)                                                              |
| Total assistance                        | 8.9 (7.1-11)                                                                | 1.16 (0.92-1.45)                                                              |
| Not reported                            | 10.8 (9.4-12.3)                                                              | 1.44 (1.23-1.69)                                                              |
| **Cause of ESKD**                       |                                                                              |                                                                              |
| Hypertension                            | 5.7 (5.3-6.2)                                                                | 1.20 (1.04-1.38)                                                              |
| Diabetes mellitus                       | 11.0 (10.5-11.5)                                                             | 1.61 (1.40-1.86)                                                              |
| Glomerulonephritis                      | 5.6 (5.2-5.9)                                                                | Reference                                                                     |
| Polycystic kidney disease               | 7.2 (6.5-8.1)                                                                | 1.11 (0.97-1.27)                                                              |
| Other                                   | 7.2 (6.5-8.0)                                                                | 1.09 (0.96-1.23)                                                              |
| **Duration of dialysis, mo**            |                                                                              |                                                                              |
| None (pre-emptive)                      | 7.8 (7.0-8.8)                                                                | 0.87 (0.74-1.01)                                                              |
| >0-24                                   | 8.4 (7.9-9.0)                                                                | Reference                                                                     |
| 25-60                                   | 7.6 (7.2-8.0)                                                                | 0.96 (0.88-1.05)                                                              |
| >60                                     | 6.9 (6.6-7.3)                                                                | 1.01 (0.92-1.12)                                                              |
| Not reported                            | 15.0 (6.5-32.5)                                                              | 1.73 (0.72-4.16)                                                              |
| **Most current PRA level, %**           |                                                                              |                                                                              |
| <10                                     | 7.4 (7.1-7.7)                                                                | Reference                                                                     |
| 10-79                                   | 7.8 (7.3-8.4)                                                                | 1.02 (0.94-1.12)                                                              |
| ≥80                                     | 6.7 (6.0-7.4)                                                                | 0.87 (0.77-0.98)                                                              |
| Not reported                            | 9.8 (8.6-11.2)                                                               | 1.15 (0.98-1.34)                                                              |

(Continued)
Among older patients (≥55 years), those treated with TMG or ALEM + no Pred (7.4%) or IL2rAb + no Pred (8.7%) had lower rates of fractures than those treated with the reference immunosuppression regimen (9.0%; Fig 3A). The rates of fractures among older patients treated with Tac, Tac + Pred (11.3%), mTORi-based (12.1%), and CsA-based (11.7%) immunosuppression regimens were numerically higher. However, in the multivariable, risk-adjusted analyses, only those who received TMG or ALEM + no Pred had a statistically lower risk of fractures (aHR, 0.83; 95% CI, 0.74-0.94).

The impact of immunosuppression on the risk of fractures also differed by sex (Fig 3B). Women had lower rates of fractures when they were placed on the steroid-sparing regimens. Compared to the risk of fractures with TMG or ALEM + triple therapy, the risk of fractures was 32% lower (aHR, 0.68; 95% CI, 0.46-1.00) among women treated with IL2rAb + No Pred and 29% lower (aHR, 0.71; 95% CI, 0.62-0.82) among women placed on the TMG or ALEM + no Pred regimen. Conversely, only men treated with TMG or ALEM + no Pred had lower rates of fractures (aHR, 0.77; 95% CI, 0.68-0.87) compared to those who received the reference regimen, whereas men treated with Tac, Tac + Pred, CsA-based, or mTORi-based regimens had a statistically increased risk of fractures compared with those placed on the reference regimen.

### DISCUSSION

Fractures can result in significant short- and long-term morbidity and mortality among kidney transplant recipients.1-3,23 In this national analysis, older patients and women were particularly at risk, with almost 10% of older patients experiencing a fracture. Among patients with a fracture, the risk of death was tripled in the 3 months after the event, and medical spending increased dramatically following the episode and remained consistently higher than that for patients without fractures. Despite the evidence of the benefits of strategies for the minimization of immunosuppression, the most common immunosuppression regimen prescribed after kidney transplantation is still triple therapy (48.7% in those aged <55 years; 40% in those aged ≥55 years), exposing many kidney transplant recipients to the long-term risks of glucocorticoids. Compared with the reference group (treated with TMG or ALEM + triple therapy), the only group who experienced a lower incidence of fractures >3 months-to-3 years after kidney transplantation, irrespective of recipient age, were those who received TMG or ALEM + no Pred. Patients

---

**Table 2 (Cont’d). Cumulative Incidence of Fractures >3 Months-to-3 Years After Kidney Transplantation by Baseline Clinical Characteristics and Adjusted Correlates of Fracture Risk**

| Baseline Characteristic | Cumulative Incidence of Fractures >3 m-to-3 y After Kidney Transplantation | Adjusted Correlates of Fracture Risk > 3 m-to-3 y After Kidney Transplantation |
|------------------------|-------------------------------------------------|-------------------------------------------------|
|                        | % (95% CI)                                       | aHR (95% CI)                                    |
| HLA mismatches         |                                                 |                                                 |
| 0 A, B, DR             | 8.6 (7.7-9.5)                                   | 1.07 (0.95-1.2)                                  |
| 0 DR                   | 7.4 (6.8-8.2)                                   | 1.02 (0.92-1.12)                                 |
| Other                  | 7.4 (7.2-7.7)                                   | Reference                                       |
| Cold ischemia time, h  |                                                 |                                                 |
| ≤12                    | 7.7 (7.4-8.1)                                   | Reference                                       |
| 13-24                  | 7.5 (7.1-7.8)                                   | 0.91 (0.84-0.99)                                 |
| 25-36                  | 7.5 (6.8-8.2)                                   | 0.92 (0.82-1.03)                                 |
| ≥37                    | 7.0 (5.8-8.4)                                   | 0.85 (0.7-1.04)                                  |
| Not reported           | 6.9 (6.0-7.8)                                   | 0.86 (0.75-1.00)                                 |
| Previous organ transplant |                                                 |                                                 |
| Yes                    | 7.9 (7.3-8.5)                                   | 1.18 (1.07-1.31)                                 |
| No                     | 7.4 (7.2-7.7)                                   | Reference                                       |
| Donor type             |                                                 |                                                 |
| Living donor           | 7.1 (6.6-7.6)                                   | 0.84 (0.76-0.94)                                 |
| Deceased, KDPI < 20    | 7.3 (6.7-7.9)                                   | 0.95 (0.86-1.04)                                 |
| Deceased, KDPI 20-85   | 7.4 (7.1-7.7)                                   | Reference                                       |
| Deceased, KDPI > 85    | 9.8 (8.9-10.7)                                  | 1.17 (1.05-1.30)                                 |
| Transplantation era    |                                                 |                                                 |
| 2005-2008              | 7.9 (7.5-8.3)                                   | Reference                                       |
| 2009-2012              | 8.1 (7.8-8.5)                                   | 1.02 (0.95-1.10)                                 |
| 2013-2016              | 6.0 (5.6-6.5)                                   | 0.73 (0.67-0.80)                                 |

Note: "Other race" includes Asian, Native American, Pacific Islander, and multiracial.
Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ESKD, end-stage kidney disease; HLA, human leukocyte antigen; KDPI, kidney donor profile index; PRA, panel-reactive antibody.

P < 0.001.
0.001 < P ≤ 0.05.
0.0001 ≤ P < 0.001.
Figure 1. The adjusted risk of death following the diagnosis of a fracture >3 months-to-3 years after kidney transplantation. Effect estimates reflect the impact of the diagnosis of a fracture as a time-varying predictor of subsequent death, partitioned in exposure time (A) within 3 months and (B) >3 months after the diagnosis of fracture. Risk was stratified by age and sex. Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; mo, month; y, year.

Table 3. Mortality Risk Associated With Fracture >3 Months-to-3 Years After Kidney Transplantation Modeled as a Time-Varying Covariate, and Partitioned by Exposure Time Within 3 Months and >3 Months After Fracture Diagnosis

| Sample Strata | aHR (95% CI) ≤3 m After Fracture | aHR (95% CI) >3 m After Fracture |
|---------------|----------------------------------|----------------------------------|
| All           | 3.06 (2.45-3.81)                 | 1.68 (1.48-1.92)                 |
| Age 18-54 y   | 2.80 (2.16-3.65)                 | 1.31 (0.98-1.76)                 |
| Age ≥ 55 y    | 3.90 (2.60-5.85)                 | 1.80 (1.56-2.09)                 |
| Men           | 3.28 (2.37-4.53)                 | 1.77 (1.49-2.09)                 |
| Women         | 2.86 (2.13-3.90)                 | 1.57 (1.28-1.93)                 |

Note: The overall and stratified models are adjusted for all other baseline recipient, donor, and transplant factors (Table 1), including continuous age. Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval.

immunosuppression regimens were associated with equivalent or higher incidences of fractures.

CKD-MBD is a systemic disorder characterized by abnormalities in the metabolism of calcium, phosphorus, parathyroid hormone, fibroblast growth factor-23, and vitamin D; abnormalities in bone turnover and mineralization; and extraskeletal calcifications. The retention of phosphate has long been thought to be the initial trigger for many of these components. Secondary hyperparathyroidism, a major feature of CKD-MBD, occurs in response to the retention of phosphate, a decreased concentration of free ionized calcium, a decreased concentration of vitamin D, an increased concentration of fibroblastic growth factor-23, and reduced expression of vitamin D and calcium-sensing receptors. In patients with advancing kidney disease, bone lesions are progressive and lead to complications such as fractures and bone pains, noted when patients undergo maintenance renal replacement therapies. Posttransplantation bone disease is significantly different from the range of CKD-MBD seen...
before transplantation and is characterized by changes in bone quality and density as well as mineral metabolism, which contribute to the increased risk of fractures.36 Following successful kidney transplantation, several key changes in mineral metabolism occur. There is rapid loss of bone mass in the early posttransplantation period, which frequently affects the trabecular bone because of decreased bone formation as a result of glucocorticoid therapy.17 The level of parathyroid hormone normalizes within 12 months after transplantation in 56.9% of patients,37 and there are improvements in the levels of calcium, phosphorus, and 1,25-dihydroxy vitamin D, which are associated with the improvements of kidney function.38 Despite these improvements, it is important to recognize that mineral homeostasis is complex and that bone remodeling continues after transplantation.36 In a prospective cohort study of 27 kidney transplant recipients who consented to a bone biopsy while still receiving dialysis and another bone biopsy 2 years after transplantation, the rate of bone turnover declined after kidney transplantation.39

Previous studies have identified many risk factors for fractures among kidney transplant recipients, including female sex, older age, lower BMI, White race, diabetes, longer duration of dialysis, poor allograft function, persistent hyperparathyroidism, uremia, acidosis, and immunosuppression therapy, especially glucocorticoids.12,20,22,40-44 Among these risk factors, older age is a strong and consistent risk factor for fractures after kidney transplantation,11,12,20,22,40-44 as also demonstrated in our study. In the current study, we assessed the impact of various immunosuppression regimens on the risk of fractures and identified a significant reduction in the risk of fractures among older (≥55 years) adults who received the TMG or ALEM + no Pred regimen. The skeletal effects of glucocorticoids include decreases in the replication, differentiation, and life span of osteoblasts.13,43,45 Additionally, glucocorticoids inhibit genes that encode type I collagen, osteocalcin, insulin-like growth factors, bone morphogenetic and other bone matrix proteins, transforming growth factor-beta, and the receptor activator for nuclear factor kappa B ligand.16,47 These combined actions result in reduced bone formation and bone density, especially in the trabecular bone, and are related to cumulative steroid exposure.13,17,48 Although the adverse effects of glucocorticoids on bone health among kidney transplant recipients have been clearly demonstrated, data on the effects of the early withdrawal or avoidance of steroids on preserved bone mass among patients who have undergone kidney transplantation are limited to several small studies,19-57 and data on the risk of fractures have been

Figure 3. Adjusted associations of immunosuppressive regimens with the risk of a fracture >3 months-to-3 years after kidney transplantation stratified by (A) age and (B) sex. Interaction between immunosuppression and recipient age: interleukin 2 receptor antibody + triple therapy (P = 0.006), antithymocyte globulin or alemtuzumab + no prednisone (P = 0.003), and mammalian target of rapamycin inhibitor-based (P = 0.003) regimens. Interaction between immunosuppression and recipient gender: interleukin 2 receptor antibody + no prednisone regimen (P = 0.04). Abbreviations: aHR, adjusted hazard ratio; ALEM, alemtuzumab; CsA, cyclosporine A; CI, confidence interval; IL2rAb, interleukin 2 receptor antibody; ISx, immunosuppression; KTx, kidney transplant; m, month; mTORi, mammalian target of rapamycin inhibitor; Ref, reference; Tac, tacrolimus; TMG, antithymocyte globulin; y, year.
limited. The findings from our current study suggest protective effects of the early withdrawal or avoidance of steroids on the risk of fractures in all age and sex subgroups of kidney transplant recipients. Given recent evidence suggesting the beneficial effects of lower-intensity immunosuppression regimens (eg, early withdrawal or avoidance of steroids) on patient and graft survival among older kidney transplant recipients, and that older kidney transplant recipients are more susceptible to immunosuppression complications such as infection and malignancies, the findings of our study also support the use of the early steroid withdrawal or avoidance for bone health among older kidney transplant recipients. Considering the conflicting and limited data on safety and clinical efficacy of treatments (including bisphosphonates, vitamin D, or denosumab) to reduce the risk of fractures after kidney transplantation, the minimization of the risk of fractures with the early withdrawal or avoidance of steroids may provide an optimal strategy for older populations who have undergone kidney transplantation.

The effect of calcineurin inhibitors, which have become a mainstay of posttransplantation maintenance immunosuppression regimens, on bone metabolism is unclear. Calcineurin inhibitors have been suggested to stimulate the loss of bone mass independent of glucocorticoid therapy, with high-turnover bone metabolism noted in rat models. However, results from human studies have not shown these effects. Although the combination of calcineurin inhibitors and corticosteroids is associated with profound uncoupling of bone remodeling and rapid bone loss, studies of kidney transplant recipients receiving CsA and a steroid-free regimen have not demonstrated significant bone loss. In a small group of kidney transplant recipients followed for 1 year, those who received Tac and low doses of steroids had a slight net increase in the bone mineral density compared those who received CsA and normal doses of steroids, who experienced a decrease in bone mineral density. Thus, these findings could have been confounded by the impact of glucocorticoids in these regimens. The effects of other immunosuppression agents have not been studied well. In rat models, the short-term use of mycophenolate mofetil did not result in decreased bone volume. In humans, patients who received CsA showed the evidence of lesser bone turnover and bone resorption compared with those who received sirolimus. Our study found an increased incidence of fractures with Tac, Tac + Pred, CsA-based, and mTORi-based regimens only in male kidney transplant recipients, and future studies evaluating underlying mechanisms are needed. The study identified a lower risk of fractures in younger patients and women treated with IL-2raAb + triple therapy than in those treated with TMG or ALEM + triple therapy. It is possible that these associations are driven by the clinical belief that these patients have less immunologic risk, allowing more rapid weaning of the total immunosuppression exposure. Previous studies have shown that kidney transplant recipients who sustain a fracture have an increased risk of mortality compared with the general population. Our analysis confirms that patients who are diagnosed with a fracture after kidney transplantation have a 3-fold increase in the risk of death during the 3 months after the event. These analyses could not determine the etiology of the increased mortality. It is possible that this association could be related to deterioration of health because of immobilization, the risk of death if fracture repair required surgery, or complications arising from the fractures themselves. Irrespective of the cause of death, it is imperative to recognize fractures as a factor that affects posttransplantation survival and that every measure possible is taken to prevent a fracture.

There are limitations to this study and its interpretation. First, bone health before transplantation plays a major role in the risk of fractures after transplantation. It is difficult to assess or classify the pretransplantation bone health status of kidney transplant recipients, especially in registry data. Second, immunosuppression choice is highly influenced by center practices and protocols. Because the US Renal Data System database does not provide center identifiers, we could not assess the impact of center on differences in the outcomes of immunosuppression. Third, the choice of immunosuppression regimen might have been affected by unaccounted risk factors in the database, such as prior rejection episodes, other donor characteristics, intolerance of standard medications, or social determinants of health. This analysis also focused on the early administration of immunosuppression (within 3 months). Patients who had fractures may have been administered steroids after the first 3 months of transplantation because of episodes of rejection. Lastly, our analysis did not differentiate among types of fractures. Fractures of the pelvis or hip, vertebra, and lower leg have been shown to be the most prevalent types of fractures based on Medicare data from patients receiving hemodialysis. It is not possible to determine whether the relative risks and benefits of immunosuppression regimens differ by the location of fractures. However, regardless of the location, fractures identified using this analytic method were associated with clinically significant impacts on patient survival and spending. Despite these limitations, the inferences presented in this analysis reflect actual risks in real-world practice.

In summary, fractures after kidney transplantation negatively affect posttransplantation survival and healthcare costs. Immunosuppression plays an important role in determining the risk of a fracture after transplantation. The incidence of fractures >3 months-to-3 years after kidney transplantation is highest in older adults and women. TMG or ALEM + no Pred substantially reduced the risk of fractures in both higher and lower-risk groups. A strong consideration of the risks of complications such as fractures, along with the risk of rejection, is necessary when choosing the appropriate immunosuppressive regimen to optimize posttransplantation outcomes.
SUPPLEMENTARY MATERIAL

Supplementary File (PDF)

Figure S1: Patient flowchart.

Figure S2: Adjusted incremental cost of fracture occurring in the first, second, or third year posttransplant (in period) and incremental cost of patient care for patients who sustained fractures in prior periods.

Table S1: International Classification of Disease, Clinical Modification, Diagnosis Codes Used to Define Medical Diagnoses From Billing Claims Data.

Table S2: Characteristics of Patients in the Study Sample Compared to Kidney Transplant Recipients Not Included in the Cohort.

Table S3: Associations of Fracture >3 Months-to-3 Years After Kidney Transplantation and Other Clinical Factors With Costs After Transplant.

Table S4: Distributions of Baseline Patient, Donor, and Transplant Factors According to Early Immunosuppression Regimen Use Among Younger Adult Kidney Transplant Recipients (Age 18-54 Years; N = 35,622).

Table S5: Distributions of Baseline Patient, Donor, and Transplant Factors According to Early Immunosuppression Regimen Use Among Older Adult Kidney Transplant Recipients (Age ≥55 Years; N = 31,740).

ARTICLE INFORMATION

Authors’ Full Names and Academic Degrees: Sarat Kuppachi, MBBS, Wissi Cheungpasitporn, MD, Ruixin Li, MS, Yasar Caliskan, MD, Mark A. Schnitzler, PhD, Mara McAdams-DeMarco, PhD, JiYoon B. Ahn, PhD, Sunjae Bae, PhD, Gregory P. Hess, MD, Dorry L. Segev, MD, PhD, Krista L. Lentine, MD, PhD, and David A. Axelrod, MD, MBA

Authors’ Affiliations: Organ Transplant Center, University of Iowa, Iowa City, IA (SK, DAA); Department of Medicine, Mayo Clinic, Rochester, MN (WC); Saint Louis University Transplant Center, Saint Louis University, St. Louis, MO (RL, YC, MAS, KLL); Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD (MM-D, JBA, SB, DLS); Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA (GPH); and Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark (GPH).

Address for Correspondence: Krista L. Lentine, MD, PhD, Saint Louis University Transplant Center, 1201 S. Grand Blvd., St. Louis, MO 63104. Email: krista.lentine@health.slu.edu

Authors’ Contributions: KLL and DAA are co-senior authors (contributed equally). Study design: KLL, DAA, SK, WC, YC, MAS, MM-D, DLS, JBA, SB, DLS; data acquisition: KLL, MAS; data analysis: RL; data interpretation: KLL, DAA, SK, WC, YC, MAS, MM-D, DLS, JBA, SB, DLS; supervision/mentorship: MAS, KLL, DAA. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Support: This work was funded by a grant from the National Institute of Diabetes and Digestive and Kidney Disease (R01DK120518). Dr Lentine is supported by the Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation.

Financial Disclosure: Dr Schnitzler reports consulting fees from CareDx. Dr Axelrod reports honoraria from Sanofi and consulting fees from CareDx and Talaris. Dr Lentine reports speaker honoraria from Sanofi and consulting fees from CareDx. The remaining authors declare that they have no relevant financial interests.

Disclaimer: The data reported here have been supplied by the US Renal Data System. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the US government.

Prior Presentation: Portions of these findings have been accepted for presentation at the 2021 American Transplant Congress virtual meeting.

Peer Review: Received December 20, 2021. Evaluated by 3 external peer reviewers, with direct editorial input from the Statistical Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form March 13, 2022.

REFERENCES

1. Ferro CJ, Arnold J, Bagnall D, Ray D, Sharif A. Fracture risk and mortality post-kidney transplantation. Clin Transplant. 2015;29(11):1004-1012.
2. Nair SS, Lenihan CR, Montez-Rath ME, Lowenberg DW, Chertow GM, Winkelmayer WC. Temporal trends in the incidence, treatment and outcomes of hip fracture after first kidney transplantation in the United States. Am J Transplant. 2014;14(4):943-951.
3. Abbott KC, Oglesby RJ, Hypolite IO, et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol. 2001;11(7):450-457.
4. Khairallah P, Nickolas TL. Management of osteoporosis in CKD. Clin J Am Soc Nephrol. 2018;13(6):962-969.
5. Nazzaal Z, Khader S, Zawyani H, Abdallah M, Sawalmeh O, Hamdan Z. Bone mineral density in Palestinian patients with end-stage renal disease and the related clinical and biochemical factors: cross-sectional study. PLoS One. 2020;15(11):e0241201.
6. Ball AM, Gillen DL, Sherrard D, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA. 2002;288(23):3014-3018.
7. Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation. 1994:58(8):912-915.
8. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725-1730.
9. Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011;11(10):2093-2109.
10. United States renal data system: 2018 USRDS annual data report: epidemiology of kidney disease in the United States B, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2018. Accessed. https://usrds.org/previous-ads/2010-2019/
11. O’Shaughnessy EA, Dahl DC, Smith CL, Kasiske BL. Risk factors for fractures in kidney transplantation. Transplantation. 2002;74(3):362-366.
12. Cuetto-Manzano AM, Konel S, Hutchison AJ, et al. Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int. 1999;55(5):2021-2029.
13. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quares LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991;325(8):544-550.
14. Vaughton LM, Melton LJ III, Clarke BL, Achenbach SJ, Oberg AL, McCarthy JT. Long-term fracture risk following renal
transplantation: a population-based study. Osteoporos Int. 2004;15(2):160-167.
15. Ramsey-Goldman R, Dunn JE, Dunlop DD, et al. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res. 1999;14(3):456-463.
16. Nikkel LE, Mohan S, Zhang A, et al. Reduced fracture risk with early corticosteroid withdrawal after kidney transplant. Am J Transplant. 2012;12(3):649-659.
17. Monier-Faugère MC, Mawad H, Qi Q, Friedler RM, Malluche HH. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol. 2000;11(6):1093-1099.
18. Malluche HH, Monier-Faugère MC, Herberth J. Bone disease after renal transplantation. Nat Rev Nephrol. 2010;6(1):32-40.
19. Nikkel LE, Hollenbeck CS, Fox EJ, Uemura T, Ghahramani N. Risk of fractures after renal transplantation in the United States. Transplantation. 2009;87(12):1846-1851.
20. Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellström B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation. 1999;67(9):1218-1222.
21. Elmsedt E. Incidence of skeletal complications in renal graft recipients: effect of changes in pharmacotherapy. Acta Orthop Scand. 1982;53(6):853-856.
22. Perrin P, Caillard S, Javier RM, et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant. 2013;13(10):2653-2663.
23. Naylor KL, Li AH, Lam NN, Hodsman AB, Jamal SA, Garg AX. Fracture risk in kidney transplant recipients: a systematic review. Transplantation. 2013;95(12):1461-1470.
24. Kodras K, Haas M. Effect of kidney transplantation on bone. Eur J Clin Investig. 2006;36(suppl 2):63-75.
25. Marcén R, Teruel JL. Patient outcomes after kidney allograft loss. Transplant Rev (Orlando). 2008;22(1):62-70.
26. Cecka JM. The OPTN/UNOS renal transplant registry. Clin Transpl. 2005:1-16.
27. Dharhindharka VR, Schnitzler MA, Chen J, et al. Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. Transpl Int. 2016;29(11):1226-1236.
28. Axelrod DA, Cheungpasitporn W, Bunnnapradist S, et al. Post-transplant diabetes mellitus and immunosuppression selection based on initial immunosuppression regimen: a national study. Transpl Int. 2016;29(11):100377.
29. Gheorghian A, Schnitzler MA, Axelrod DA, Kalsekar A, L’Italier G, Lentine KL. The implications of acute rejection and reduced allograft function on health care expenditures in contemporary US kidney transplantation. Transplantation. 2012;94(3):241-249.
30. Dharhindharka VR, Naik AS, Axelrod D, et al. Clinical and economic consequences of early cancer after kidney transplantation in contemporary practice. Transplantation. 2017;101(4):858-866.
31. Naik AS, Dharhindharka VR, Schnitzler MA, et al. Clinical and economic consequences of first-year urinary tract infections, sepsis, and pneumonia in contemporary kidney transplantation practice. Transpl Int. 2016;29(2):241-252.
32. Martin KJ, González EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol. 2007;18(3):875-885.
33. Fang Y, Ginsberg C, Sugatani T, Monier-Faugère MC, Malluche H, Hruska KA. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int. 2014;85(1):142-150.
34. Isakova T, Cai X, Lee J, et al. Longitudinal evolution of markers of mineral metabolism in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis. 2020;75(2):235-244.
35. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995;333(3):166-174.
36. Bouquegneau A, Salam S, Delaney P, Eastell R, Khwaja A. Bone disease after kidney transplantation. Clin J Am Soc Nephrol. 2016;11(7):1282-1296.
37. Lou I, Foley D, Odorico SK, et al. How well does renal transplantation cure parathyroidism? Ann Surg. 2015;262(4):653-659.
38. Wolf M, Weir MR, Kopyt N, et al. A prospective cohort study of mineral metabolism after kidney transplantation. Transplantation. 2016;100(1):184-193.
39. Keronen S, Martola L, Finne P, Burton IS, Kröger H, Honkanen E. Changes in bone histomorphometry after kidney transplantation. Clin J Am Soc Nephrol. 2019;14(6):894-903.
40. Torregrosa JV, Campistol JM, Montesinos M, Pons F, de Osaba MM. Evolution of bone mineral density after renal transplantation: related factors. Nephrol Dial Transplant. 1995;10(suppl 6):111-113.
41. Giannini S, Selia S, Silva Netto F, et al. Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: role of calcium-sensing receptor polymorphisms and vitamin D deficiency. J Bone Miner Res. 2010;25(4):841-848.
42. Pichette V, Bonnardeaux A, Prudhomme L, Gagné M, Cardinal J, Ouimet D. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis. 1996;28(1):105-114.
43. Horber FF, Casez JP, Steiger U, Czerniak A, Montandon A, Jaeger P. Changes in bone mass early after kidney transplantation. J Bone Miner Res. 1994;9(1):1-9.
44. Briner VA, Thiel G, Monier-Faugère MC, et al. Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation. Transplantation. 1995;59(10):1393-1400.
45. Mikuls TR, Julian BA, Bartolucci A, Saag KG. Bone mineral density changes within six months of renal transplantation. Transplantation. 2003;75(1):49-54.
46. Moreno A, Torregrosa JV, Pons F, Campistol JM, de Osaba MM, Oppenheimer F. Bone mineral density after renal transplantation: long-term follow-up. Transplant Proc. 1999;31(6):2322-2323.
47. Grotz WH, Mundinger FA, Gugel B, Exner VM, Kirste G, Schollmeyer PJ. Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation. 1995;59(7):982-986.
48. Stein E, Ebeling P, Shane E. Post-transplantation osteoporosis. Endocrinol Metab Clin North Am. 2007;36(4):937-963.
49. Aroldi A, Tarantino A, Montagino G, Cesana B, Cocucci C, Ponticelli C. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplantation. 1997;63(3):380-386.
50. Farmer CK, Hampson G, Abbas IC, et al. Late low-dose steroid withdrawal in renal transplant recipients increases bone formation and bone mineral density. Am J Transplant. 2006;6(12):2929-2936.
51. van den Ham EC, Koopman JP, Christiaans ML, van Hooff JP. The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients. Transpl Int. 2003;16(2):82-87.
52. Ing SW, Sinnott LT, Donepudi S, Davies EA, Pelletier RP, Lane NE. Change in bone mineral density at one year following glucocorticoid withdrawal in kidney transplant recipients. Clin Transplant. 2011;25(2):E113-E123.
53. Lentine KL, Cheungpasitporn W, Xiao H, et al. Immunosuppression regimen use and outcomes in older and younger adult kidney transplant recipients: a national registry analysis. *Transplantation*. 2021;105(8):1840-1849.

54. Cheungpasitporn W, Lentine KL, Tan JC, et al. Immunosuppression considerations for older kidney transplant recipients. *Curr Transplant Rep*. 2021;8(2):100-110.

55. Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. *Cochrane Database Syst Rev*. 2007;3(3):CD005015.

56. Alferi C, Binda V, Malvica S, et al. Bone effect and safety of one-year denosumab therapy in a cohort of renal transplanted patients: an observational monocentric study. *J Clin Med*. 2021;10(9):1989.

57. Thongprayoon C, Acharya P, Aeddula NR, et al. Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis. *Arch Osteoporos*. 2019;14(1):1-13.

58. Kirino S, Fukunaga J, Ikekami S, et al. Regulation of bone metabolism in immunosuppressant (FK506)-treated rats. *J Bone Miner Metab*. 2004;22(6):554-560.

59. Cvetkovic M, Mann GN, Romero DF, et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. *Transplantation*. 1994;57(8):1231-1237.

60. Epstein S, Dissanayake IR, Goodman GR, et al. Effect of the interaction of parathyroid hormone and cyclosporine a on bone mineral metabolism in the rat. *Calci Tissue Int*. 2001;68(4):240-247.

61. Voggenreiter G, Siozos P, Hunkemöller E, Heute S, Schwarz M, Obertacke U. Immunosuppression with FK506 has no influence on fracture healing in the rat. *Bone*. 2005;37(2):227-233.

62. Ponticelli C, Aroldi A. Osteoporosis after organ transplantation. *Lancet*. 2001;357(9268):1623.

63. McIntyre HD, Menzies B, Rigby R, Perry-Keene DA, Hawley CM, Hardie IR. Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. *Clin Transplant*. 1995;9(1):20-24.

64. Goffin E, Devogelaer JP, Lalauji A, et al. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. *Transpl Int*. 2002;15(2):73-80.

65. Dissanayake IR, Epstein S. The fate of bone after renal transplantation. *Curr Opin Nephrol Hypertens*. 1998;7(4):389-395.

66. Campistol JM, Holt DW, Epstein S, et al. Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. *Transpl Int*. 2005;18(9):1028-1035.

67. Axelrod DA, Naik AS, Schnitzler MA, et al. National variation in use of immunosuppression for kidney transplantation: a call for evidence-based regimen selection. *Am J Transplant*. 2016;16(8):2453-2462.

68. Beaubrun AC, Kilpatrick RD, Freburger JK, Bradbury BD, Wang L, Brookhart MA. Temporal trends in fracture rates and postdischarge outcomes among hemodialysis patients. *J Am Soc Nephrol*. 2013;24(9):1461-1469.
What are the clinical and economic implications of fractures in kidney transplant recipients?

**Methods**
Retrospective database study
US Renal Data System & Medicare billing claims 2005 - 2016

**Results**

| Fracture risk (aHR, 95% CI) | Women (vs. men) | Age ≥ 55 (vs. < 55) |
|-----------------------------|-----------------|-------------------|
| Fracture development > 3months-to-3years after KTx | 1.42 (1.33, 1.52) | 1.26 (1.18, 1.35) |

**Mortality risk at ≤3 months after fracture**

| Medicare spending associated with fractures within: | 1st year after KTx | 2nd year after KTx | 3rd year after KTx |
|---------------------------------------------------|-------------------|-------------------|-------------------|
| Fracture development > 3months-to-3years after KTx | $5,122 | $10,890 | $11,082 |

**Conclusion:** Fracture after KTx is associated with significantly increased fracture risk and costs. Early steroid withdrawal after induction with TMG/ALEM reduces the risk of fracture after KTx and should be considered for high-risk patients including older adults and women.

**Reference:** Kuppachi S, Cheungpasitporn W, Li R et al. Kidney transplantation immunosuppression and risk of fracture: clinical and economic implications. *Kidney Medicine*, 2022.

Visual abstract by Corina Teodosiu, MD